To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
180
Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants
Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
Primary Effectiveness Endpoint : AAA Sac Regression at 1 year
The percentage of subjects showing regression, defined as sac volume reduction of ≥10% at 1 year (in comparison to the 30 day CT), and no AAA-related intervention through 1 year.
Time frame: 1 year
Primary Safety Endpoint : Major Adverse Event (MAE) Rate through 30 days
Freedom from the following through 30 days post-index procedure: * Major adverse events (MAEs) which include the following: all-cause mortality, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, procedural blood loss \>1000 mL. * AAA-rupture or AAA-perforation * Conversion to Open Repair
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alabama Birmingham
Birmingham, Alabama, United States
Honor Health
Scottsdale, Arizona, United States
USC Keck
Los Angeles, California, United States
San Diego VA Medical Center
San Diego, California, United States
Delray Medical Center
Delray Beach, Florida, United States
Mt. Sinai Medical Center
Miami Beach, Florida, United States
Orlando Health
Orlando, Florida, United States
University of South Florida
Tampa, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
...and 39 more locations